Skip to content

Case Study: Manufacturing iPSC-derived skeletal muscle cells

By Karin Langenberg

Development of a scalable manufacturing process for human iPSC-derived skeletal muscle cells

Human induced pluripotent stem cells (iPSCs) have the ability to self-renew, while maintaining the potential to differentiate into nearly any functional cell type in the body. With the adequate expertise and capabilities, human iPSC technology can be used to bring human biology earlier in drug discovery to facilitate decision-making steps. Ncardia has over 10 years of experience developing iPSCs and has well-established processes to manufacture several human iPSC-derived lineages. Additionally, our highly skilled scientific team and in-house equipment allow us to develop and establish custom processes for the differentiation and large-scale manufacturing of any required iPSC-derived cell type.

This case study describes how Ncardia successfully developed a scalable manufacturing process for human iPSC-derived skeletal muscle cells.

Manufacturing iPSC-derived skeletal muscle cells

Download the case study to:

  • Discover our cost- and time-efficient approach to develop new scalable manufacturing processes
  • Learn how we used high-content imaging to assess the quality and phenotipic identity of the manufactured skeletal muscle cells.

Get a PDF version using the form below.